Tag Archives: MURA spinoff

Xoma To Buy Failed Mural, Ending The Short, Unsuccessful Run Of The Alkermes Spinoff

By |
0 Comment

Barely 2 weeks ago, Mural Oncology(MURA) announced it would be winding down operations, and likely returning any remaining cash to shareholders. We estimated that the value to shareholders of the 2023 Alkermes(ALKS) spinoff would be slightly less than $2, a disappointing outcome, but at least not a total loss. Today, Mural announced it had agreed to be acquired… Read More »

Mural Oncology Paints Itself Into A Corner After Nemvaleukin Alfa Fails

By |
1 Comment
mural oncology wind down

  In November 2023, Alkermes plc (ALKS) spun off its oncology division into a new company: Mural Oncology plc (MURA). Armed with $275 million in cash, no debt, and a clean slate, the company was designed as a single-focus biotech aimed at bringing nemvaleukin alfa, an engineered IL-2 cytokine, through late-stage development. Less than two years later, the… Read More »